JP2017511321A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511321A5
JP2017511321A5 JP2016559887A JP2016559887A JP2017511321A5 JP 2017511321 A5 JP2017511321 A5 JP 2017511321A5 JP 2016559887 A JP2016559887 A JP 2016559887A JP 2016559887 A JP2016559887 A JP 2016559887A JP 2017511321 A5 JP2017511321 A5 JP 2017511321A5
Authority
JP
Japan
Prior art keywords
cancer
formula
alkyl
independently
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559887A
Other languages
English (en)
Japanese (ja)
Other versions
JP6756435B2 (ja
JP2017511321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023362 external-priority patent/WO2015153468A1/en
Publication of JP2017511321A publication Critical patent/JP2017511321A/ja
Publication of JP2017511321A5 publication Critical patent/JP2017511321A5/ja
Application granted granted Critical
Publication of JP6756435B2 publication Critical patent/JP6756435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559887A 2014-03-31 2015-03-30 Ｔｒａｉｌ誘導のためのファーマコフォア Active JP6756435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
US61/972,689 2014-03-31
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019164086A Division JP6873201B2 (ja) 2014-03-31 2019-09-10 Ｔｒａｉｌ誘導のためのファーマコフォア

Publications (3)

Publication Number Publication Date
JP2017511321A JP2017511321A (ja) 2017-04-20
JP2017511321A5 true JP2017511321A5 (enExample) 2018-05-10
JP6756435B2 JP6756435B2 (ja) 2020-09-16

Family

ID=54241169

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016559887A Active JP6756435B2 (ja) 2014-03-31 2015-03-30 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2019164086A Active JP6873201B2 (ja) 2014-03-31 2019-09-10 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2021071035A Active JP7186256B2 (ja) 2014-03-31 2021-04-20 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2022188821A Active JP7688245B2 (ja) 2014-03-31 2022-11-28 Ｔｒａｉｌ誘導のためのファーマコフォア

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019164086A Active JP6873201B2 (ja) 2014-03-31 2019-09-10 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2021071035A Active JP7186256B2 (ja) 2014-03-31 2021-04-20 Ｔｒａｉｌ誘導のためのファーマコフォア
JP2022188821A Active JP7688245B2 (ja) 2014-03-31 2022-11-28 Ｔｒａｉｌ誘導のためのファーマコフォア

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3662910B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102473930B1 (enExample)
CN (2) CN106456643B (enExample)
AU (4) AU2015241069B2 (enExample)
CA (2) CA2944452C (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3125898T3 (enExample)
ES (2) ES2779979T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE049013T2 (enExample)
LT (2) LT3125898T (enExample)
PL (2) PL3125898T3 (enExample)
PT (2) PT3662910T (enExample)
RS (2) RS60163B1 (enExample)
SI (2) SI3125898T1 (enExample)
SM (2) SMT202000219T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191181T1 (hr) 2013-03-13 2019-10-04 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
CN106163524B (zh) * 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
HUE049013T2 (hu) 2014-03-31 2020-08-28 Scripps Research Inst Farmakofór trail indukcióra
PT3250208T (pt) * 2015-01-30 2021-01-06 Oncoceutics Inc 7-benzil-4-(4-trifluorometil)benzil)-1,2,6,7,8,9-hexa-hidroimidazo[1,2- a]pirido[3,4-e]pirimidin-5(4h)-ona e sais do mesmo e seu em terapias
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
KR102801670B1 (ko) * 2016-01-29 2025-04-25 온코슈틱스 인코포레이티드 이미프리돈에 의한 g 단백질-커플링된 수용체 (gpcr) 조절
WO2018031987A1 (en) 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
CA3131740A1 (en) 2019-02-27 2020-09-03 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
CA3190787A1 (en) 2020-08-06 2022-02-10 Eotvos Lorand Tudomanyegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
AU2003299517A1 (en) * 2002-05-23 2004-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2959793A1 (en) * 2008-06-09 2009-12-17 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
UA113508C2 (xx) * 2011-03-15 2017-02-10 Ізоксазолідинові похідні
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
PT3679934T (pt) * 2011-04-29 2024-09-05 Penn State Res Found Indução do gene trail de pequenas moléculas por células normais e tumorais enquanto terapia anticancro
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
HRP20191181T1 (hr) * 2013-03-13 2019-10-04 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
HUE049013T2 (hu) 2014-03-31 2020-08-28 Scripps Research Inst Farmakofór trail indukcióra

Similar Documents

Publication Publication Date Title
JP2017511321A5 (enExample)
EP4328229A3 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
JP2019512478A5 (enExample)
JP2018504379A5 (enExample)
JP2017536344A5 (enExample)
JP2017509586A5 (enExample)
JP2016503799A5 (enExample)
JP2018507197A5 (enExample)
JP2019518766A5 (enExample)
JP2015537020A5 (enExample)
RU2013130253A (ru) 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения
IN2014MN02106A (enExample)
JP2013544846A5 (enExample)
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
JP2018504437A5 (enExample)
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
JP2014051526A5 (enExample)
JP2017525730A5 (enExample)
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
JP2013537203A5 (enExample)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
JP2015512943A5 (enExample)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
JP2016529319A5 (enExample)